We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis (MuSicalE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03593590
Recruitment Status : Active, not recruiting
First Posted : July 20, 2018
Last Update Posted : August 23, 2022
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a multicentre non-interventional study aimed at evaluating the real-world effectiveness and safety of ocrelizumab treatment in participants with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS), who have been prescribed ocrelizumab as per routine practice. This study will use a comprehensive combination of participant reported outcomes and conventional multiple sclerosis (MS) endpoints that measure clinical domains commonly affected by MS (e.g. fatigue, hand function, gait, cognition), and their impact on employment, activities of daily living, quality of life and healthcare resource utilization. The incidence, type, and pattern of serious adverse events (SAEs), and of adverse events (AEs) leading to treatment discontinuation will also be determined.

Condition or disease Intervention/treatment
Multiple Sclerosis Drug: Ocrelizumab

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1700 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Multicentre Non-interventional Study to Assess the Real-world Effectiveness of Ocrelizumab in Patients With Relapsing or Primary Progressive Multiple Sclerosis - The MuSicalE STUDY
Actual Study Start Date : November 12, 2018
Estimated Primary Completion Date : July 26, 2025
Estimated Study Completion Date : July 26, 2025

Resource links provided by the National Library of Medicine

Drug Information available for: Ocrelizumab

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Ocrelizumab
Participants with relapsing or primary progressive MS receiving ocrelizumab under routine clinical care.
 Drug: Ocrelizumab
Ocrelizumab is administered as an intravenous infusion in accordance with the approved labelling.
Other Name: Ocrevus


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Changes in the overall SymptoMScreen score in participants with RMS [ Time Frame: 4 years ]

    SymptoMScreen is a battery of 7-point Likert scales for 12 distinct domains: mobility, dexterity, body pain, sensation, bladder function, fatigue, vision, dizziness, cognition, depression, and anxiety.

    Composite scores (range min: 0, max: 72) Subscores for each functional domain (range: 0-not affected at all; 6: total limitation/I'm unable to do most daily activities)


  2. Changes in the overall SymptoMScreen score in participants with PPMS [ Time Frame: 4 years ]

    SymptoMScreen is a battery of 7-point Likert scales for 12 distinct domains: mobility, dexterity, body pain, sensation, bladder function, fatigue, vision, dizziness, cognition, depression, and anxiety.

    Composite scores (range min: 0, max: 72) Subscores for each functional domain (range: 0-not affected at all; 6: total limitation/I'm unable to do most daily activities)



Secondary Outcome Measures :
  1. Percentage of RMS Participants with Adverse Events [ Time Frame: 4 years ]
  2. Percentage of PPMS participants with Adverse Events [ Time Frame: 4 years ]
  3. Time to treatment discontinuation due to adverse events with ocrelizumab in participants with RMS [ Time Frame: 4 years ]
  4. Time to treatment discontinuation due to adverse events with ocrelizumab in participants with PPMS [ Time Frame: 4 years ]
  5. Change in the score of Multiple Sclerosis Impact Scale (MSIS-29) in RMS participants [ Time Frame: 4 years ]
  6. Change in the score of Multiple Sclerosis Impact Scale (MSIS-29) in PPMS participants [ Time Frame: 4 years ]
  7. Change in the score of ABILHAND - 56 scale in RMS participants [ Time Frame: 4 years ]
  8. Change in the score of ABILHAND - 56 scale in PPMS participants [ Time Frame: 4 years ]
  9. Change in the score of Fatigue Scale Motor and Cognitive functions (FSMC) in RMS participant [ Time Frame: 4 years ]
  10. Change in the score of Fatigue Scale Motor and Cognitive functions (FSMC) in PPMS participants [ Time Frame: 4 years ]
  11. Change in the score of Treatment Satisfaction Questionnaire for Medication (TSQM) in RMS participants [ Time Frame: 4 years ]
  12. Change in the score of Treatment Satisfaction Questionnaire for Medication (TSQM) in PPMS participants [ Time Frame: 4 years ]
  13. Change in the score of MSWS - 12 scale in RMS participants [ Time Frame: 4 years ]
  14. Change in the score of MSWS - 12 scale in PPMS participants [ Time Frame: 4 years ]
  15. Changes in proportion of patients employed/non-employed, number of inpatient days, hospital admissions, medication use and associated costs over the course of the study, captured by the MS-COI in RMS Participants [ Time Frame: 4 years ]
  16. Changes in proportion of patients employed/non-employed, number of inpatient days, hospital admissions, medication use and associated costs over the course of the study, captured by the MS-COI in PPMS Participants [ Time Frame: 4 years ]
  17. Frequency of relapses over time in RMS patients [ Time Frame: 4 years ]
  18. Disease progression in participants with RMS as measured by Expanded Disability Status Scale (EDSS) over time [ Time Frame: 4 years ]
  19. Disease progression in participants with PPMS as measured by Expanded Disability Status Scale (EDSS) over time [ Time Frame: 4 years ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Participants with RMS or PPMS undergoing routine clinical care
Criteria

Inclusion Criteria:

  • Must have a definite diagnosis of RMS or PPMS and in whom a decision to initiate ocrelizumab has been taken as part of routine clinical practice
  • Must be prescribed ocrelizumab in line with the SmPC
  • Must have provided signed informed consent
  • Must be able and willing to complete the PROs as per clinical practice

Exclusion Criteria:

  • Previously treated with ocrelizumab (including phase II, phase III and phase IIIB clinical trials, local trials and investigator initiated study (IIS) as well as a pre-approval access or compassionate use programmes or local registries that are not compatible with the MuSicalE study design)
  • Not receiving ocrelizumab in line with the SmPC
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03593590


Locations
Show Show 165 study locations
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT03593590    
Other Study ID Numbers: MN39889
First Posted: July 20, 2018    Key Record Dates
Last Update Posted: August 23, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Multiple Sclerosis, Chronic Progressive
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
 Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Ocrelizumab
Immunologic Factors
Physiological Effects of Drugs